The impact of human immunodeficiency virus infection on drug-resistant tuberculosis.
Infection with human immunodeficiency virus (HIV) has been associated with increased rates of single- and multidrug-resistant (MDR) tuberculosis in the New York City area. In order to examine the relationship of HIV infection to drug-resistant tuberculosis in other selected regions of the United States, we established a registry of cases of culture-proven tuberculosis. Data were collected from sites participating in an NIH-funded, community-based HIV clinical trials group. All cases of tuberculosis, regardless of HIV status, which occurred between January 1992 and June 1994 were recorded. Overall, 1,373 cases of tuberculosis were evaluated, including 425 from the New York City area, and 948 from seven other metropolitan areas. The overall prevalence of resistance to one or more drugs was 20.4%, and 5.6% of isolates were resistant to both isoniazid and rifampin (MDR). In the New York City area, HIV-infected patients were significantly more likely than persons not known to be HIV-infected, to have resistance to at least one drug (37% versus 19%) and MDR (19% versus 6%). In other geographic areas, overall drug resistance was 16%, and only 2.2% of isolates were MDR. In multiple logistic regression analyses, HIV infection was shown to be a risk factor for drug-resistant tuberculosis, independent of geographic location, history of prior therapy, age, and race. We concluded that HIV infection is associated with increased rates of resistance to antituberculosis drugs in both the New York City area and other geographic areas. MDR tuberculosis is occurring predominantly in the New York City area and is highly correlated with HIV infection.
Gordin
F M
FM
Division of Infectious Diseases, Department of Veterans Affairs Medical Center, Washington, DC, USA. Terry Beirn Community Programs for Clinical Research on AIDS.
Nelson
E T
ET
Matts
J P
JP
Cohn
D L
DL
Ernst
J
J
Benator
D
D
Besch
C L
CL
Crane
L R
LR
Sampson
J H
JH
Bragg
P S
PS
El-Sadr
W
W
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006703:Ill-Housed Persons; D006716:Homosexuality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009519:New York City / Q000453:epidemiology; D015995:Prevalence; D012042:Registries; D018088:Tuberculosis, Multidrug-Resistant / Q000453:epidemiology / Q000209:etiology*; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control; D014481:United States / Q000453:epidemiology; D014505:Urban Population
D000995:Antitubercular Agents